Center for Clinical and Translational Science

摘要 由新型SARS-COV-2病毒引发的大流行继续对健康造成毁灭性影响 在临床上、社会上和经济上都是社区的。预防性方法需要了解 一般人群中的病毒流行率和群体免疫水平。作为先前自然历史的一部分 临床与翻译科学中心(CCTS；阿拉巴马大学伯明翰分校[UAB]) 与匹兹堡大学临床和翻译科学研究所(CTSI)和 国家过敏症和传染病研究所(NIAID)传染病实验室(LID) 协调开展国家新冠肺炎血清预防接种项目。这项研究建立了一个几乎具有代表性的国家- 对11,300名尚未被诊断为感染病毒的参与者进行广泛队列调查，以提供生物检疫药物 评估全美的基线免疫力。要检验随时间变化的人口流行率， 可检测到的SARS-COV-2抗体，这是学术医学中心和NIH的科学合作伙伴关系 内部研究计划将召回并重新同意已建立的队列提交额外的血液 从最初的登记日期到6个月和12个月的时间点的样本和临床信息 了解全国新冠肺炎免疫力变化(目标1)。新获得的生物制品将是 用于确定与健康结果相关的免疫属性，包括特殊或 在整个生命过程中代表不足的人口和个人(目标2)。这项工作得益于深度 在传染病的基础和应用研究以及病毒疫苗开发方面的专业知识 国家过敏和遗传学研究所的病毒免疫反应和病毒分子生物学和遗传学 传染病(NIAID)。它还利用了临床和医疗中心维护的严谨高效的能力 UAB和匹兹堡的翻译科学奖(CTSA)中心迅速吸引不同的 国家参与者加速翻译研究，这是科学上和最终高度优先的 公共卫生实践。从这项研究中，协作团队将获得对纵向 世卫组织将在全国范围内应对新冠肺炎大流行的影响，并将确定疫苗的潜在靶点。这些 数据对于评估公共卫生努力的影响和指导正在进行的新冠肺炎应对至关重要。

ABSTRACT The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating impact on the health of communities, clinically, socially and economically. Preventive approaches require an understanding of the virus prevalence and the level of herd immunity in the general population. As part of a previous natural history study, the Center for Clinical and Translational Science (CCTS; University of Alabama at Birmingham [UAB]) collaborated with the University of Pittsburgh Clinical and Translational Science Institute (CTSI) and the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease (LID) to coordinate a national COVID-19 seroprevalence project. This study established a near-representative, nation- wide cohort of 11,300 participants who had not been diagnosed with the virus to provide biospecimens to evaluate baseline immunity across the United States. To examine the time-dependent population prevalence of detectable antibodies to SARS-COV-2, this scientific partnership of academic medical centers and the NIH’s intramural research program will recall and re-consent the established cohort to submit additional blood specimens and clinical information at 6- and 12-month time points from their original enrollment date to understand changes in COVID-19 immunity across the country (Aim 1). Newly obtained biospecimens will be used to determine the immune attributes associated with health outcomes, including outcomes in special or underrepresented populations and individuals across the life course (Aim 2). This work benefits from the deep expertise in the basic and applied research of infectious diseases as well as viral vaccine development, host immune response to viruses, and viral molecular biology and genetics at the National Institute for Allergy and Infectious Diseases (NIAID). It also leverages the rigorous and efficient capacity maintained by Clinical and Translational Science Awards (CTSA) Hubs at UAB and Pittsburgh to rapidly engage diverse cohorts of participants nationally to accelerate translational research that is high priority scientifically and for eventual public health practice. From this study, the collaborative team will gain crucial insights into the longitudinal impact of the COVID-19 pandemic across the country and will identify potential targets for a vaccine. These data are essential to assess the impact of public health efforts and to guide ongoing COVID-19 response.